These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7057824)

  • 1. Reversal of aluminum-induced hemodialysis anemia by a low-aluminum dialysate.
    O'Hare JA; Murnaghan DJ
    N Engl J Med; 1982 Mar; 306(11):654-6. PubMed ID: 7057824
    [No Abstract]   [Full Text] [Related]  

  • 2. Aluminium-induced, reversible microcytic anemia in chronic renal failure: clinical and experimental studies.
    Touam M; Martinez F; Lacour B; Bourdon R; Zingraff J; Di Giulio S; Drüeke T
    Clin Nephrol; 1983 Jun; 19(6):295-8. PubMed ID: 6872366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
    Abreo K; Brown ST; Sella M; Trapp G
    J Lab Clin Med; 1989 Jan; 113(1):50-7. PubMed ID: 2909650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A study of anemia in 86 patients on hemodialysis (author's transl)].
    Serra A; Camps J; Morlans M; Olmos A; Carrera A; Soriano B; Rodríguez JA; Pelegrí A; Bartolomé J; Piera L
    Med Clin (Barc); 1981 May; 76(10):439-43. PubMed ID: 7242164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of aluminum on hematopoiesis.
    Drüeke TB; Lacour B; Touam M; Jucquel JP; Plachot JJ; Cournot-Witmer G; Galle P
    Kidney Int Suppl; 1986 Feb; 18():S45-8. PubMed ID: 3457995
    [No Abstract]   [Full Text] [Related]  

  • 6. [Evaluation of iron therapy in patients in long-term haemodialysis (author's transl)].
    Serra A; Morlans M; Olmos A; Camps J; Rodríguez JA; Carreras A; Soriano B; Bartolomé J; Piera L
    Med Clin (Barc); 1982 Apr; 78(8):313-7. PubMed ID: 7087599
    [No Abstract]   [Full Text] [Related]  

  • 7. [Anemia and iron stores in patients during hemodialysis and after renal transplantation [].
    Piedras J; Córdova MS; Alvarez-Hernández X; Wadgymar A; Hernández G; Peña JC
    Rev Invest Clin; 1982; 34(2):129-32. PubMed ID: 6750733
    [No Abstract]   [Full Text] [Related]  

  • 8. [Sideropenic anemia in patients under periodic hemodialysis treatment: efficacy and safety of oral iron treatment].
    Recchia G; Gulino S; Dean P; Prati G; Firpo M; Galvani E; Muolo A; Ancona G
    Clin Ter; 1984 Mar; 108(5):397-404. PubMed ID: 6232076
    [No Abstract]   [Full Text] [Related]  

  • 9. [Iron requirements of hemodialysis patients. Serum ferritin as an indicator].
    Hunderi OH
    Tidsskr Nor Laegeforen; 1986 Apr; 106(9):738-40. PubMed ID: 3705034
    [No Abstract]   [Full Text] [Related]  

  • 10. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminium intoxication.
    Short AI; Winney RJ; Robson JS
    Proc Eur Dial Transplant Assoc; 1980; 17():226-33. PubMed ID: 7243773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive dialysis encephalopathy from dialysate aluminum.
    Rozas VV; Port FK; Rutt WM
    Arch Intern Med; 1978 Sep; 138(9):1375-7. PubMed ID: 686928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of ultrapure dialysate on improving renal anemia.
    Go I; Takemoto Y; Tsuchida K; Sugimura K; Nakatani T
    Osaka City Med J; 2007 Jun; 53(1):17-23. PubMed ID: 17867630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of continuous ambulatory peritoneal dialysis on anemia in uremic patients.
    Marcovici O; Boner G; Rosenfeld JB
    Isr J Med Sci; 1983 Jul; 19(7):604-7. PubMed ID: 6885343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aluminum in tissues.
    Van de Vyver FL; De Broe ME
    Clin Nephrol; 1985; 24 Suppl 1():S37-57. PubMed ID: 3915959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microcytic anemia secondary to intraperitoneal aluminum in normal and uremic rats.
    Kaiser L; Schwartz KA; Burnatowska-Hledin MA; Mayor GH
    Kidney Int; 1984 Sep; 26(3):269-74. PubMed ID: 6513272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
    Swartz R; Dombrouski J; Burnatowska-Hledin M; Mayor G
    Am J Kidney Dis; 1987 Mar; 9(3):217-23. PubMed ID: 3826071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aluminium chelation therapy in dialysis patients: evidence for inhibition of haemoglobin synthesis by low levels of aluminium.
    Altmann P; Plowman D; Marsh F; Cunningham J
    Lancet; 1988 May; 1(8593):1012-5. PubMed ID: 2896867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of aluminum in the pathogenesis of anemia in an outpatient hemodialysis population.
    Yuan B; Klein MH; Contiguglia RS; Mishell JL; Seligman PA; Miller NL; Molitoris BA; Alfrey AC; Shapiro JI
    Ren Fail; 1989; 11(2-3):91-6. PubMed ID: 2623200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of captopril-bound Fe by end-stage renal failure patients during hemodialysis.
    Averbukh Z; Berman S; Kishinevsky E; Feldman L; Cohn M; Rapoport M; Galperin E; Dishi V; Weissgarten J
    J Nephrol; 2004; 17(1):101-6. PubMed ID: 15151265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Red blood cells indices and aluminium toxicity in haemodialysis patients.
    Tielemans C; Kalima L; Collart F; Wens R; Smeyers-Verbeke J; Verbeelen D; Dratwa M
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():395-8. PubMed ID: 3991530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.